OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Medical Economics is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	99
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych	90
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	56
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	51
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	42
Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective	38
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	37
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	36
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	35
Projected clinical and economic benefits of improved patent foramen ovale testing among cryptogenic stroke patients in the United States	34
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	33
Economic value of intra-articular knee OA therapies: a U.S. perspective	33
The economic burden of systemic lupus erythematosus in Taiwan	32
Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries	28
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	28
Economic review of point-of-care EEG	27
Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury	24
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective	23
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	22
Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity	22
Challenges in health economics research: insights from real-world examples	22
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease	21
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment	21